Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;23(6):826-32.
doi: 10.1016/j.jvir.2012.02.010. Epub 2012 Apr 14.

Radiofrequency ablation: effect of tumor- and organ-specific pharmacologic modulation of arterial and portal venous blood flow on coagulation diameter in an N1-S1 tumor model

Affiliations

Radiofrequency ablation: effect of tumor- and organ-specific pharmacologic modulation of arterial and portal venous blood flow on coagulation diameter in an N1-S1 tumor model

Luke R Wilkins et al. J Vasc Interv Radiol. 2012 Jun.

Abstract

Purpose: To investigate inherent differences in vasculature of tumors versus normal parenchyma and efficacy of radiofrequency (RF) ablation with glucagon, adenosine, and a combination of the two compared with normal saline solution (NS) controls in an N1-S1 tumor model implanted in Sprague-Dawley rat livers.

Materials and methods: A total of 17 tumors were established in the left lobes of rats. Tumor perfusion relative to surrounding liver parenchyma was evaluated with contrast-enhanced ultrasound with intermittent-bolus technique before and after administration of glucagon, adenosine, a combination of the two, or NS. Tumors were ablated with a 22-gauge RF probe with 1 cm of exposed tip at 80 °C for 2 min. Tumor size, zone of necrosis, and viable tumor were measured in tumors after 2,3,5-triphenyltetrazolium chloride staining. Results were compared with degree of tumor perfusion.

Results: The normalized tumor perfusion ratio did not significantly change with administration of NS (1.38% ± 3.93). Vasomodulation resulted in significant decreases in normalized tumor perfusion ratio: 66.22% ± 24.57 (P < .01) with glucagon, 71.45% ± 22.72 (P < .01) with adenosine, and 74.98% ± 16.58 (P < .01) with glucagon plus adenosine. After tumor ablation, there was an increase in size of the ablated area by 100%-165% in the three treatment groups compared with NS controls. Differences among treatment groups were not statistically significant.

Conclusions: Tumor blood flow may be significantly altered by using systemic injection of appropriate medications. This tumor- and organ-specific approach to tumor vasomodulation may be used to enhance current therapeutic options.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative method of assessing relative tumor perfusion prior to (above) and following Adenosine + Glucagon (AD+GN) (below). Circle 1 within tumor and cicle 2 within normal liver. Graphs show decrease in ratio of A β in tumor versus A β in liver reflecting relative tumor hypoperfusion following vasomodulation with AD+GN.
Figure 2
Figure 2
Post-ablation Tumors stained with 2% TTC. Dash line reflects border of ablated tumor. Solid line indicates border of viable tumor. NS = normal saline. AD = adenosine. GN = glucagon.
Figure 3
Figure 3
Graph simultaneously comparing vasomodulation agents and normal saline (NS) control compared with area of ablation (cm2) (left y-axis) and change in relative tumor perfusion ratio (%) (right y-axis). AD = adenosine. GN = glucagon.

References

    1. Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiol. 2004;233:729–739. - PubMed
    1. Bertrand J, Sofocleous C, Hanna N, et al. Development of a Research Agenda for the Management of Metastatic Colorectal Cancer: Proceedings from a Multidisciplinary Research Consensus Panel. J Vasc Interv Radiol. 2012;23:153–163. - PMC - PubMed
    1. McWilliams JP, Yamamoto S, Raman SS, et al. Percutaneous Ablation of Hepatocellular Carcinoma: Current Status. J Vasc Interv Radiol. 2010;21:S204–S213. - PubMed
    1. Hori T, Nagata K, Hasuike S, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol. 2003;38:977–981. - PubMed
    1. Yamakado K, Nakatsuka A, Kobayashi S, et al. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience. Cardiovasc Intervent Radiol. 2006;29:389–394. - PubMed

Publication types

MeSH terms